Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Geneoscopy, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Geneoscopy, Inc.

Regulatory records
6
Linked recall entries
1
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 6 FDA records to the applicant name Geneoscopy, Inc.. It includes 1 original PMA approval. 3 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from May 3, 2024 to Sep 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code SBB appears in 6 of the 6 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P230001, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 2220 Welsch Industrial Ct., St. Louis, MO, 63146. Recorded on P230001/S014, decision dated Sep 8, 2026.

Changes described in PMA records

P230001/S014: ColoSense

FDA’s recorded scope: ColoSense Sample preservative shelf-life extension from the original PMA approval of 12 months to 18 months in this current supplement S014.

Sep 8, 2026 · Real-Time Process

P230001/S012: ColoSense

FDA’s recorded scope: ColoSense is intended for the qualitative detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults, 45 years of age or older, who are at typical average-risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Aug 27, 2026 · Normal 180 Day Track

P230001/S011: ColoSense

FDA’s recorded scope: approval for modifying the concentration of a reagent used in the manufacturing process of QC materials and the qualification of an alternate reagent supplier

Oct 24, 2025 · 30-Day Notice

P230001/S010: ColoSense

FDA’s recorded scope: approval to modify the volume of specific kit reagents during the manufacturing process

Aug 14, 2025 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

RECALL COVERAGE

Recalls linked to this firm

MedtechLedger links 1 FDA enforcement entry through the recorded recalling firm or an exact submission number published in FDA’s recall data. 1 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.

Recall / productCompanyClassificationReport dateSource
Geneoscopy, Inc.Class IIJul 9, 2025FDA

Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.

Source information

Source updated Nov 11, 2026. Retrieved Nov 20, 2026.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
ColoSenseP230001/S014
Geneoscopy, Inc.PMA supplementSep 8, 2026FDA
ColoSenseP230001/S012
Geneoscopy, Inc.PMA supplementAug 27, 2026FDA
ColoSenseP230001/S011
Geneoscopy, Inc.PMA supplementOct 24, 2025FDA
ColoSenseP230001/S009
Geneoscopy, Inc.PMA supplementSep 15, 2025FDA
ColoSenseP230001/S010
Geneoscopy, Inc.PMA supplementAug 14, 2025FDA
ColoSenseP230001
Geneoscopy, Inc.PMA approvalMay 3, 2024FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.